Bambusa Therapeutics, a Boston, MA-based biotechnology company focused on developing bispecific antibodies for the treatment of immunological and inflammatory (I&I) disorders, raised approx. $15M in Series Seed funding.
The round was co-led by BVF Partners L.P. and Dawn Biopharma, with participation from Salvia GmbH and INCE Capital.
The company intends to use the funds to accelerate the development of its pipeline of bispecific antibodies to Phase I clinical studies.
Led by CEO Dr. Shanshan Xu, and Co-Founder Helmut Jeggle, Bambusa Therapeutics is a biotechnology company specializing in developing transformative inflammatory and immunological therapeutics. The company leverages validated targets to create bispecific antibody therapeutics through innovative antibody engineering, with an aim to achieve best-in-disease profiles for multiple indications.
FinSMEs
09/09/2024